Table 2.
Incidence of events and hazard ratios of drug groups for all events during 6 month follow-up
| Patient-years | Number of events | Incidence of event per 1000 patient-years |
Hazard ratio |
||
|---|---|---|---|---|---|
| Crude | Adjusted | ||||
| Ischaemic heart disease | |||||
| NRT | 52 289 | 2148 | 41·1 | 1 | 1 |
| Bupropion | 3246 | 52 | 16·0 | 0·39 (0·30–0·51) | 0·67 (0·51–0·89) |
| Varenicline | 25428 | 594 | 23·4 | 0·57 (0·52–0·62) | 0·80 (0·72–0·87) |
| Cerebral infarction | |||||
| NRT | 52 705 | 871 | 16·5 | 1 | 1 |
| Bupropion | 3259 | 18 | 5·5 | 0·33 (0·21–0·53) | 0·55 (0·35–0·89) |
| Varenicline | 25 557 | 164 | 6·4 | 0·39 (0·33–0·46) | 0·62 (0·52–0·73) |
| Heart failure | |||||
| NRT | 52 895 | 302 | 5·7 | 1 | 1 |
| Bupropion | 3262 | 7 | 2·1 | 0·38 (0·18–0·80) | 0·71 (0·33–1·51) |
| Varenicline | 25 588 | 52 | 2·0 | 0·36 (0·27–0·48) | 0·61 (0·45–0·83) |
| Peripheral vascular disease | |||||
| NRT | 52 849 | 430 | 8·1 | 1 | 1 |
| Bupropion | 3259 | 14 | 4·3 | 0·53 (0·31–0·90) | 0·83 (0·48–1·41) |
| Varenicline | 25 563 | 123 | 4·8 | 0·59 (0·48–0·72) | 0·82 (0·67–1·01) |
| Arrhythmia | |||||
| NRT | 52 815 | 563 | 10·7 | 1 | 1 |
| Bupropion | 3260 | 14 | 4·3 | 0·40 (0·24–0·69) | 0·66 (0·39–1·13) |
| Varenicline | 25 561 | 126 | 4·9 | 0·46 (0·38–0·56) | 0·73 (0·60–0·88) |
| Depression | |||||
| NRT | 50 558 | 8274 | 163·7 | 1 | 1 |
| Bupropion | 3162 | 357 | 112·9 | 0·69 (0·62–0·77) | 0·75 (0·67–0·83) |
| Varenicline | 24 965 | 2395 | 95·9 | 0·59 (0·56–0·61) | 0·66 (0·63–0·69) |
| Self-harm | |||||
| NRT | 52 832 | 540 | 10·2 | 1 | 1 |
| Bupropion | 3259 | 20 | 6·1 | 0·60 (0·38–0·94) | 0·74 (0·48–1·16) |
| Varenicline | 25 570 | 119 | 4·7 | 0·46 (0·37–0·56) | 0·56 (0·46–0·68) |
Data in parentheses are 95% CIs. NRT=nicotine replacement treatment.